4dk8
From Proteopedia
(Difference between revisions)
(One intermediate revision not shown.) | |||
Line 1: | Line 1: | ||
==Crystal structure of LXR ligand binding domain in complex with partial agonist 5== | ==Crystal structure of LXR ligand binding domain in complex with partial agonist 5== | ||
- | <StructureSection load='4dk8' size='340' side='right' caption='[[4dk8]], [[Resolution|resolution]] 2.75Å' scene=''> | + | <StructureSection load='4dk8' size='340' side='right'caption='[[4dk8]], [[Resolution|resolution]] 2.75Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4dk8]] is a 4 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[4dk8]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4DK8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4DK8 FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=0KT:N-METHYL-N-(4-{(1S)-2,2,2-TRIFLUORO-1-HYDROXY-1-[1-(2-METHOXYETHYL)-1H-PYRROL-2-YL]ETHYL}PHENYL)BENZENESULFONAMIDE'>0KT</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.75Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=0KT:N-METHYL-N-(4-{(1S)-2,2,2-TRIFLUORO-1-HYDROXY-1-[1-(2-METHOXYETHYL)-1H-PYRROL-2-YL]ETHYL}PHENYL)BENZENESULFONAMIDE'>0KT</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr> | |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4dk8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4dk8 OCA], [https://pdbe.org/4dk8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4dk8 RCSB], [https://www.ebi.ac.uk/pdbsum/4dk8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4dk8 ProSAT]</span></td></tr> | |
- | + | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
- | == Disease == | ||
- | [[http://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Note=A chromosomal aberration involving NCOA1 is a cause of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3 generates the NCOA1-PAX3 oncogene consisting of the N-terminus part of PAX3 and the C-terminus part of NCOA1. The fusion protein acts as a transcriptional activator. Rhabdomyosarcoma is the most common soft tissue carcinoma in childhood, representing 5-8% of all malignancies in children. | ||
== Function == | == Function == | ||
- | [ | + | [https://www.uniprot.org/uniprot/NR1H2_HUMAN NR1H2_HUMAN] Orphan receptor. Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity). |
- | + | ||
- | + | ||
- | + | ||
- | + | ==See Also== | |
- | + | *[[Liver X receptor|Liver X receptor]] | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: Kopecky | + | [[Category: Kopecky DJ]] |
- | [[Category: Piper | + | [[Category: Piper DE]] |
- | [[Category: Xu | + | [[Category: Xu H]] |
- | + | ||
- | + | ||
- | + |
Current revision
Crystal structure of LXR ligand binding domain in complex with partial agonist 5
|